Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
US7001598B2 · kind B2 · utility
24Cited by
0References
132Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 16, 2001 |
| Grant date | Feb 21, 2006 |
| Priority date | — |
| Expiry date | Sep 19, 2022 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/809
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to compositions and methods useful for treating or reducing the advancement, severity or effects of neoplasia by the administration of at least two or more lymphotoxin beta receptor (LT-β receptor) activating agents where at least one LT-β receptor activating agent is an anti-LT-β receptor antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.